NCI awards Fred Hutch $24 million to operate contact center for patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI awarded $24 million to Fred Hutchinson Cancer Research Center to continue operating the NCI’s primary public access point for cancer information in both English and Spanish.

With the new contract, the Contact Center will emphasize clinical trial education and referrals, increasing outreach to medically underserved populations and integrating innovative communication technologies.

“We are constantly adapting to meet people’s information-seeking needs,” said Nancy Gore, director of the Contact Center, which provides free phone and online help to cancer patients and their families. “The sophistication of our clients has certainly increased over time because of what they’ve been able to access and read online about their conditions before contacting us. Now they often need to know how or whether specific information applies to their case, and that’s where we are able to provide additional context and education, including questions to take back to their health care provider to help further their understanding.”

NCI originally established contact centers at several NCI-designated cancer centers throughout the country; the first call was taken in 1976. The Contact Center at Fred Hutch joined this effort in 1981, and eventually became the sole operator in 2009, when NCI consolidated existing operations into a single Contact Center.

Gore has worked at the Contact Center at Fred Hutch for 23 years and manages a team of about 65 employees, including cancer information specialists who answer inquiries and oncology-certified nurses who provide technical assistance on interactions and are members of the training team for new staff.

The group handled close to 92,000 inquiries last year, 48 percent by phone and 43 percent by live chat. While the number of calls has decreased over time — a trend seen at other contact centers — questions through the live-chat option are on the rise. The Fred Hutch team also responds to questions that come through email, which makes up 8 percent of inquiries. A sliver of inquiries, 1 percent, come through social media. People can reach the service Monday through Friday, 9 a.m. – 9 p.m. ET by calling 1.800.4.CANCER (800.422.6237), through online live chat or by email on NCI’s website www.cancer.gov. Bilingual (English-Spanish) staff members are available on all access channels.

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login